Avoidance of doxorubicin resistance in osteosarcoma cells using a new quinoline derivative, MS-209

Anticancer Research

Volumn 18, Issue 2 A, 1998, Pages 739-742

  Takeshita, Hideyuki ^a,b   Kusuzaki, Katsuyuki ^a   Tsuji, Yoshiro ^a   Hirata, Masazumi ^a   Hashiguchi, Shin ^a   Nakamura, Shin Ichiro ^a   Murata, Hiroaki ^a   Ashihara, Tsukasa ^a   Hirasawa, Yasusuke ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b Otsu Municipal Hospital   (Japan)

Author keywords

Doxorubicin; Drug resistance; MS 209; Osteosarcoma; P glycoprotein

Indexed keywords

5 [3 (4 DIPHENYLACETYL 1 PIPERAZINYL) 2 HYDROXYPROPOXY]QUINOLINE; ANTINEOPLASTIC AGENT; CYCLOSPORIN A; DOXORUBICIN; GLYCOPROTEIN P; QUINOLINE DERIVATIVE; TACROLIMUS; UNCLASSIFIED DRUG; VERAPAMIL;

ARTICLE; CANCER CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; HUMAN; HUMAN CELL; OSTEOSARCOMA; OSTEOSARCOMA CELL; PRIORITY JOURNAL;

EID: 0031812589     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Chen CJ, Chin JE, Ueda K, Clark DP, Pastan I, Gottesman MM, and Roninson IB: Internal duplication and homology with bacterial transport proteins in the mdrl (P-glycoprotein) gene from multidrug resistant human cells. Cell 47: 381-389, 1986.
2. Gerlach JH, Endicott JA, Juranka PF, Henderson G, Sarangi F, Deuchars KI, and Ling V: Homology between P-glycoprotein and a bacterial haemolysin transport protein suggests a mode for multidrug resistance. Nature 324: 485-489, 1986.
3. Chan HSL, Haddad G, Thorner PS, Deboer G, Lin UP, Ondrusek N, Yerger H and Ling V: P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. N Engl J Med 325: 1608-1614, 1991.
4. Baldini N, Scotlandi K, Barbanti-Brodano G, Manara MC, Maurici D, Bacci G, Bertoni F, Picci P, Sottili S, Campanacci M and Serra M: P-glycoprotein expression and outcome in high grade osteosarcoma. N Engl J Med 333: 1380-1385, 1995.
5. Miller RL, Bukowski RM, Budd GT, Purvis J. Weick JK, Shepard K, Midha KK and Ganapathi R: Clinical modulation of doxorubicin resistance by the calmodulin-inhibitor, trifluoperazine: a phase I/II trial. J Clin Oncol 6: 880-888, 1988.
6. Miller TP, Grogan TM, Dalton WS, Spier CM, Scheper RJ and Salmon SE: P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. J Clin Oncol 9: 17-24, 1991.
7. Bartlett NL, Lum BL, Fisher GA, Brophy NA, Ehsan MN, Halsey J and Sikic BI: Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance. J Clin Oncol 12: 835-842, 1994.
8. Fojo AT, Ueda K, Slamon DJ, Poplack DJ, Gottesman MM and Pastan I: Expression of a multidrug resistance gene in human tumors and tissues. Proc Natl Acad Sci USA 84: 7785-7789, 1986.
9. Sugahara I, Kataoka I, Morishita Y, Turuo T, Itoyama S and Mori S: Tissue distribution of P-glycoprotein encoded by multidrug-resistant gene as revealed by a monoclonal antibody, MRK16. Cancer Res 48: 1926-1929, 1987.
10. Boesch D, Muller K, Pourtier-ManzaNedo A, and Loor F: Restoration of daunomycin retention in multidrug resistant P388 cells by micromolar concentrations of SDZ PSC 833, a nonimmunosuppressive cyclosporine derivative. Exp Cell Res 196: 26-32, 1991.
11. Sato W, Fukuzawa N, Suzuki T Yusa K and Turuo T: Circumvention of multidrug resistance by a newly synthesized quinoline derivative, MS-073. Cancer Res 51: 2420-2424, 1991.
12. Takeshita H, Gebhardt MC, Springfield DS, Kloen P, Jennings C, and Mankin HJ: Biological characterization of a newly developed adriamycin-resistant murine osteosarcoma cell line. In: Frontiers of osteosarcoma research.Interdisciplinary survey of clinical and research advances.(Novak JF and McMaster JH, eds). Seattle, Hogfere & Hurber Publ, 1993, pp 239-241, 550.
13. Takeshita H, Gebhardt MC, Springfield DS, Kusuzaki K and Mankin HJ: Experimental models for the study of drug resistance in osteosarcoma; P-glycoprotein-positive murine osteosarcoma cell lines. J Bone Joint Surg 78-A: 366-375, 1996.
14. Sato W, Fukazawa N, Nakanishi O, Baba M, Suzuki T, Yano O, Naito M and Tsuruo T: Reversal of multidrug resistance by a novel quinoline derivative, MS-209. Cancer Chemother Pharmacol 35: 271-277, 1995.
15. Hansen MB, Nielsen SE, and Berg K: Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J Immunol Methods 119: 203-210, 1989.
16. Turuo T, Iida H, Tsukagoshi S and Sakurai Y: Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro thorough enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 41: 1967-1972, 1981.
17. Cordon-Card C, O'brien JP, Casals D, Rittman-Grauer L, Biedler JL, Melamed MR and Bertino JR: Multidrug resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci USA 86: 695-698, 1989.
18. Tatsuya T, Naito M, Ohhara T, Sugawara I and Tsuruo T: Functional involvement of P-glycoprotein in blood-brain barrier. J Biol Chem 267: 20383-20391, 1992.